ArticleJournal of clinical pathology2006
c-myc amplifications in primary breast carcinomas and their local recurrences.
Article in Journal of clinical pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- MYC regulates CSF1 expression via microRNA 17/20a to modulate tumor-associated macrophages in osteosarcoma.JCI insight · 2023Article
- MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding.Cancer research communications · 2022Article
- Article
- BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.Breast cancer research : BCR · 2020Article
- Importance of Copy Number Alterations ofJournal of medical biochemistry · 2019Article
- Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women.Annals of diagnostic pathology · 2018Article
- Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure.Journal of pancreatic cancer · 2018Review
- MYC overexpression with its prognostic and clinicopathological significance in breast cancer.Oncotarget · 2017Article
- MYCbase: a database of functional sites and biochemical properties of Myc in both normal and cancer cells.BMC bioinformatics · 2017Article
- High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer.Oncotarget · 2017Article
- MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.Journal of translational medicine · 2016Article
- MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.British journal of cancer · 2016Article
- SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation.Digestive diseases and sciences · 2015Article
- Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential.BMC systems biology · 2015Review
- C-myc as a predictive marker for chemotherapy in metastatic breast cancer.Clinical and experimental medicine · 2012Article
- FGFR1 is amplified during the progression of in situ to invasive breast carcinoma.Breast cancer research : BCR · 2012Article
- MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2012Article
- MYC and metastasis.Cancer research · 2011Review
- Estrogen receptor alpha expression in podocytes mediates protection against apoptosis in-vitro and in-vivo.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas.
methodsc-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation.
results11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients.
conclusionsWhile c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.